Overview: DNAJB9 Immunohistochemistry TestIntroduction: The DNAJB9 Immunohistochemistry Test detects DNAJB9 protein to diagnose fibrillary glomerulonephritis, causing kidney issues. Following 2023 ASN guidelines, it uses immunohistochemistry for high specificity, supporting renal screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in histopathology for patients with suspected kidney disorders.
Other Names: DNAJB9 IHC Assay, Fibrillary Glomerulonephritis Test.
FDA Status: Laboratory-developed test (LDT), meeting histopathology standards for diagnostic accuracy.
Historical Milestone: DNAJB9 testing for fibrillary glomerulonephritis emerged in the 2010s. Immunohistochemistry-based methods improved diagnostic precision for renal pathology.
Purpose: Detects DNAJB9 protein to diagnose fibrillary glomerulonephritis, guides treatment, and evaluates patients with kidney issues.
Test Parameters: 1. DNAJB9 Protein
Pretest Condition: No fasting required. Collect tissue via biopsy. Report history of kidney issues, proteinuria, or renal dysfunction.
Specimen: 0.5-2 cma³ tissue (FFPE). Transport in a biohazard container.
Sample Stability at Room Temperature: 7 days
Sample Stability at Refrigeration: Not refrigerated
Sample Stability at Frozen: Not frozen
Medical History: Document kidney issues, proteinuria, hematuria, or family history of renal disorders. Include current medications, especially immunosuppressants.
Consent: Written consent required, detailing the tests purpose, renal implications, and risks of biopsy.
Procedural Considerations: Uses immunohistochemistry to detect DNAJB9 protein in tissue. Results are available in 1-2 days, supporting rapid clinical decisions. Performed in laboratories, often for renal pathology.
Factors Affecting Result Accuracy: Improper tissue fixation or processing can affect results. Low tissue quality may reduce staining accuracy.
Clinical Significance: Positive DNAJB9 staining confirms fibrillary glomerulonephritis, guiding immunosuppressive therapy. Negative results may require further renal pathology testing.
Specialist Consultation: Consult a nephrologist for result interpretation and treatment planning.
Additional Supporting Tests: Congo red staining, electron microscopy, or renal function tests to assess kidney disorders.
Test Limitations: Specific to fibrillary glomerulonephritis; other renal conditions may require additional testing. Clinical correlation is needed.
References: ASN Renal Pathology Guidelines, 2023; Kidney International, Nasr SH, 2022.
